Market Place
Sourcing Support
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy
22 Nov 2024 //
PR NEWSWIRE
Kura Oncology Reports Q3 2024 Financial Results
07 Nov 2024 //
GLOBENEWSWIRE
Kura Oncology Presents KOMET-007 Ziftomenib Data at ASH 2024
05 Nov 2024 //
GLOBENEWSWIRE
Kura Oncology to Report Third Quarter 2024 Financial Results
31 Oct 2024 //
GLOBENEWSWIRE
Kura Oncology Reports Preclinical Data For Ziftomenib In GIST
24 Oct 2024 //
GLOBENEWSWIRE
Kura Oncology Presents KO-2806 Data with KRAS Inhibitors
23 Oct 2024 //
GLOBENEWSWIRE
Kura Oncology Publishes Ziftomenib Ph 1 Results In The Lancet
30 Sep 2024 //
GLOBENEWSWIRE
Kura Oncology Adds Michael Vasconcelles to Board
17 Sep 2024 //
GLOBENEWSWIRE
Kura Oncology To Participate In Cantor Healthcare Event
10 Sep 2024 //
GLOBENEWSWIRE
Kura Oncology Announces FDA Clearance Of IND For Ziftomenib In GIST
08 Aug 2024 //
GLOBENEWSWIRE
Kura Oncology Reports Second Quarter 2024 Financial Results
08 Aug 2024 //
GLOBENEWSWIRE
Kura Oncology to Report Second Quarter 2024 Financial Results
01 Aug 2024 //
GLOBENEWSWIRE
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Jul 2024 //
GLOBENEWSWIRE
Kura Reports Preclinical Data on Menin Inhibitor`s Potential in Diabetes
24 Jun 2024 //
GLOBENEWSWIRE
Life Science Cares San Diego Teams With Kura For Nutrition Support
11 Jun 2024 //
BUSINESSWIRE
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Jun 2024 //
GLOBENEWSWIRE
Kura Oncology to Participate in Jefferies Global Healthcare Conference
29 May 2024 //
GLOBENEWSWIRE
Kura Completes Ziftomenib NPM1-Mutant AML Trial Enrollment
14 May 2024 //
GLOBENEWSWIRE
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
08 May 2024 //
GLOBENEWSWIRE
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 May 2024 //
GLOBENEWSWIRE
Kura Oncology Reports First Quarter 2024 Financial Results
02 May 2024 //
GLOBENEWSWIRE
Kura Oncology to Report First Quarter 2024 Financial Results
25 Apr 2024 //
GLOBENEWSWIRE
Kura Gets Ziftomenib BTD In NPM1-Mutant AML
22 Apr 2024 //
GLOBENEWSWIRE
Kura Oncology to Participate in Stifel Targeted Oncology Forum
10 Apr 2024 //
GLOBENEWSWIRE
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Apr 2024 //
GLOBENEWSWIRE
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib
06 Mar 2024 //
GLOBENEWSWIRE
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Mar 2024 //
GLOBENEWSWIRE
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 //
GLOBENEWSWIRE
Kura Doses First Patient in KOMET-008 Trial of Ziftomenib with Standards of Care
26 Feb 2024 //
GLOBENEWSWIRE
Kura Oncology to Participate in Three Upcoming Investor Conferences
22 Feb 2024 //
GLOBENEWSWIRE
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
20 Feb 2024 //
GLOBENEWSWIRE
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Feb 2024 //
GLOBENEWSWIRE
Kura Reports Positive Ziftomenib Combination Data in Acute Myeloid Leukemia
30 Jan 2024 //
GLOBENEWSWIRE
Kura Oncology Announces Oversubscribed $150 Million Private Placement
24 Jan 2024 //
GLOBENEWSWIRE
Kura Oncology™s Menin Inhibitor Ziftomenib Selected for PedAL Trial
08 Dec 2023 //
GLOBENEWSWIRE
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
28 Nov 2023 //
GLOBENEWSWIRE
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration
02 Nov 2023 //
GLOBENEWSWIRE
Kura Oncology Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
Kura Oncology to Participate in Three Upcoming Investor Conferences
30 Oct 2023 //
GLOBENEWSWIRE
Kura Oncology to Report Third Quarter 2023 Financial Results
26 Oct 2023 //
GLOBENEWSWIRE
Kura Oncology Announces First Patient Dosed in FIT-001 Trial
19 Oct 2023 //
GLOBENEWSWIRE
Kura Announces Positive Results from Registration-Directed Study of Tipifarnib
17 Oct 2023 //
GLOBENEWSWIRE
Kura Oncology Announces Three Presentations at International Conference
04 Oct 2023 //
GLOBENEWSWIRE
Kura Oncology Reports Preclinical Data Showing Ability of KO-2806
28 Sep 2023 //
GLOBENEWSWIRE
Kura Oncology to Participate in Cantor Global Healthcare Conference 2023
19 Sep 2023 //
GLOBENEWSWIRE
Kura Oncology Appoints Brian Powl as Chief Commercial Officer
14 Aug 2023 //
GLOBENEWSWIRE
Kura Oncology Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Kura Oncology to Report Second Quarter 2023 Financial Results
27 Jul 2023 //
GLOBENEWSWIRE
Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock
14 Jun 2023 //
GLOBENEWSWIRE
Kura Oncology Announces Commencement of Public Offering of Common Stock
13 Jun 2023 //
GLOBENEWSWIRE
Kura Oncology Presents Late-Breaking Data for Menin Inhibitor Ziftomenib
11 Jun 2023 //
GLOBENEWSWIRE
Kura Announces Late-Breaking Abstract Accepted for Oral Presentation at 2023
30 May 2023 //
GLOBENEWSWIRE
Kura Oncology to Participate in Two Upcoming Investor Conferences
23 May 2023 //
GLOBENEWSWIRE
Kura Oncology Reports First Quarter 2023 Financial Results
10 May 2023 //
GLOBENEWSWIRE
Kura Oncology to Participate in JMP Securities Life Sciences Conference
09 May 2023 //
GLOBENEWSWIRE
Kura Oncology to Report 1Q 2023 Financial Results
03 May 2023 //
GLOBENEWSWIRE
Kura Oncology to Participate in Stifel Targeted Oncology Days
18 Apr 2023 //
GLOBENEWSWIRE
Kura Oncology Reports Preclinical Data Highlighting Farnesyl Transferase
17 Apr 2023 //
GLOBENEWSWIRE
Kura Oncology Announces Acceptance of Two Abstracts for Presentation at AACR
14 Mar 2023 //
GLOBENEWSWIRE
Kura Oncology to Participate in Upcoming Investor Conferences
01 Mar 2023 //
GLOBENEWSWIRE
